CSA Medical

Focus: CSA Medical is a Lexington, MA-based biotech founded in 2020 specializing in spray cryotherapy technology for oncology and respiratory indications. The company operates as an early-stage medical device/therapeutic innovator with a focused pipeline across gastrointestinal, pulmonary, and thoracic applications.

Oncology Respiratory

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About CSA Medical

AI assessmentNot Hiring

No open roles listed right now. Follow CSA Medical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

21 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

CSA System

Barrett Esophagus

N/A

Clinical Trials (1)

NCT00321958Study of Cryotherapy Treatment of Barrett's Esophagus and Early Esophageal Cancer

N/A

Help build intelligence for CSA Medical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused platform technology (spray cryotherapy) with 21 pipeline programs across multiple indications suggesting strong IP moat and scalability potential
Mix of early-stage (Phase 1/2 for RejuvenAir in lung neoplasms) and late-stage programs (multiple Phase 4 registries in Barrett's esophagus, lung cancer, COPD) offering diverse career paths
Founded 2020 with oncology and respiratory focus positions the company in high-unmet-need markets with potential for meaningful clinical impact

Watch Out For

Zero active job openings reported and no hiring department data suggests company may be in stealth/capital-raising mode with limited near-term expansion
Pre-revenue biotech status with no disclosed funding, revenue, or cash position creates existential risk; financial runway unknown and fundraising success unconfirmed
Limited publications (0 reported) and no disclosed FDA warnings or clinical milestones suggest early-stage program maturity with longer path to regulatory approval and commercial validation

Generated by Claude from CSA Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Metered cryospray

COPD (Chronic Obstructive Pulmonary Disease)

N/A

Clinical Trials (1)

NCT07468617Repeat Treatment With Metered Cryospray in Patients With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis

N/A

CryoSpray Ablation(tm)Thoracic Patient Registry

Lung Cancer

N/A

Clinical Trials (1)

NCT00785239CryoSpray Ablation(tm)Thoracic Patient Registry

N/A